ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

13 links2 made here, not in the record24 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04802759A Study Evaluating theEfficacy and Safety ofMultiple TreatmentCombinations inParticipants With BreastCancerHoffmann-La RochePhase 1/Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 6 · ClinicalTrials.gov record · Version of 2026-10-06Nov 3 · ClinicalTrials.gov record · Version of 2026-11-03Version of 2026-11-03CONDITIONSNeoplasm MetastasisThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionDRUGSGiredestrantIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedAbemaciclibIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerIpatasertibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedInavolisibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRibociclibIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerEverolimusIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSamuraciclibIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPertuzumab/Trastuzumab/Hyal…Entry “PH FDC SC”, read by our name r…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPalbociclibIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerAtezolizumabIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerTrastuzumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · BackgroundBackgroundPertuzumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Giredestrant

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Giredestrant”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Tested
Tested · 1
Background · 1

All judgments on this study

WhenLinkJudgeDecisionState
Oct 6The record itselfClinicalTrials.gov recordVersion of 2026-10-06Record change
Nov 2Trastuzumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 3GiredestrantClaude Opus 5.5TestedCurrent
Nov 3AbemaciclibClaude Opus 5.5Background · partnerCurrent
Nov 3IpatasertibClaude Opus 5.5TestedCurrent
Nov 3InavolisibClaude Opus 5.5TestedCurrent
Nov 3RibociclibClaude Opus 5.5Background · partnerCurrent
Nov 3EverolimusClaude Opus 5.5BackgroundCurrent
Nov 3SamuraciclibClaude Opus 5.5TestedCurrent
Nov 3Pertuzumab/Trastuzumab/Hyaluronidase-zzxfClaude Opus 5.5TestedCurrent
Nov 3PalbociclibClaude Opus 5.5Background · partnerCurrent
Nov 3AtezolizumabClaude Opus 5.5Background · partnerCurrent
Nov 3Pertuzumabmade hereClaude Opus 5.5Background · optionCurrent
Nov 3The record itselfClinicalTrials.gov recordVersion of 2026-11-03Record change
Nov 14Neoplasm MetastasisRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18GiredestrantRule based · role ruleBackgroundOverridden
Nov 18AbemaciclibRule based · role ruleBackgroundAgrees
Nov 18IpatasertibRule based · role ruleTestedAgrees
Nov 18InavolisibRule based · role ruleTestedAgrees
Nov 18RibociclibRule based · role ruleBackgroundAgrees
Nov 18EverolimusRule based · role ruleBackgroundAgrees
Nov 18SamuraciclibRule based · role ruleTestedAgrees
Nov 18Pertuzumab/Trastuzumab/Hyaluronidase-zzxfRule based · role ruleTestedAgrees
Nov 18PalbociclibRule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees
As of nowNeoplasm MetastasisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.